American Society of Hirudotherapy

Investigation of kinetic parameters in vitro of serine proteinases included in the blood coagulation cascade

Enzymology study published in Protein and Peptide Letters (2006)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSalivary PharmacologyDanalev DL · Protein and peptide letters, 2006

Abstract

During the last years the cases and death due to hemostatic violations exceed that of tumors. Enormous efforts have devoted to the prevention and treatment of some diseases such as arterial thrombosis. Antistasin, a 15 kDa anticoagulant protein isolated from salivary glands of the Mexican leech Haementeria officinalis, has been shown to be a potent inhibitor of Factor Xa in the blood coagulation cascade. Some short analogues which are hybrid structure between isoform 2 and 3 of antistasin and tripeptides inhibitors of serine proteinases were synthesized and reported in our previous work. Inhibitor constants, mechanism, and type of inhibition of some short analogues of antistasin are investigated. These analogs which show high anticoagulant activity in vitro in pure platelet human plasma.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsBlood CoagulationHumansKineticsModels, BiologicalSerine Endopeptidases

Summary

Investigates kinetic parameters of serine proteinases in the coagulation cascade as targets for leech-derived antistasin-type inhibitors and ghilantens.

Why This Matters for Hirudotherapy

This in-vitro study examined the inhibitory kinetics (inhibitor constants, mechanism, and type of inhibition) of short synthetic analogues of antistasin — a ~15 kDa Factor Xa-inhibiting anticoagulant protein from the salivary glands of the Mexican leech Haementeria officinalis — built as hybrids of antistasin isoforms 2 and 3 with tripeptide serine-proteinase inhibitors, reporting high anticoagulant activity in pure human platelet plasma. For hirudotherapy this is squarely part of the medicinal-leech secretome drug-discovery story: it illustrates how a leech-derived protein motif can be miniaturized into defined Factor Xa-targeting molecules, complementing the better-known thrombin inhibitor hirudin. The honest caveat is that these are bench-only kinetic measurements in isolated plasma — there are no animal or human data here, so the findings speak to molecular design potential, not to clinical use of leech therapy.

Citation

Investigation of kinetic parameters in vitro of serine proteinases included in the blood coagulation cascade.

Danalev DL · Protein and peptide letters, 2006

DOI

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.